The legal processing of possible health damage from the Covid 19 vaccinations will pick up speed in Germany in the coming months. According to information from WELT AM SONNTAG, the first civil lawsuit against the Mainz-based vaccine manufacturer Biontech for alleged health damage from the Covid-19 vaccination in Germany will begin on March 15th.
The Frankfurt am Main district court, where the civil trial is taking place, confirmed the date. The case involves a 57-year-old woman who claims to have suffered heart damage from being vaccinated with Biontech's Comirnaty vaccine. She is therefore demanding damages.
Biontech stated that every suspected case of a potential vaccination side effect is examined “medically and legally”, but the plaintiff did not provide “enough information”, which is why there was no basis for an examination. Biontech did not want to give specific information about the ongoing process.
According to information from WELT AM SONNTAG, further civil lawsuits against Biontech for alleged vaccine damage will take place at the end of March in Frankenthal, in May in Düsseldorf and in August in Munich. The respective regional courts have confirmed the dates to WELT AM SONNTAG. According to information from WELT AM SONNTAG, a first declaratory action has also been brought against the federal government, which wants to clarify whether the corresponding statutory ordinance for the procurement of vaccines is legal.
Meanwhile, demands for compensation for people with proven vaccination damage are increasing in politics. “Anyone who has been proven to have suffered vaccination damage must be adequately compensated for it. A federal special fund could be an appropriate instrument," said Tino Sorge, health policy spokesman for the CDU/CSU parliamentary group.
Ates Gürpinar, spokesman for hospital and care policy for the Left Group, called for those affected to be helped "quickly and unbureaucratically". "The federal government must ensure that there is a contact person and that those affected are not left alone," said Gürpinar.